Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840837 · ClinicalTrials.gov registry record · Phase 4
Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT03840837 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 31 participants.
The verdict
NCT03840837, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a single-site non-randomized open label pilot study. The investigators will use accelerometer-based instrumented gait analysis and computerized cognitive testing to study the interaction of motor and cognitive dysfunction in Parkinson disease dementia (PDD), and the effect of rivastigmine on motor and cognitive performance. All study participants will be tested for motor and cognitive performance at baseline (arm 1). A subgroup of study participants will then be treated with rivastigmine for 12 weeks (arm 2), and the effect of this treatment on gait measures and cognitive measures will be analyzed at the follow-up visit 12 weeks after the baseline visit. Specifically, we will determine which components of motor and cognitive impairment are associated with each other, and which components of the two domains respond to rivastigmine-mediated stimulation of cholinergic neurotransmission.
Interventions
- DRUG Rivastigmine transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03840837
The ClinicalTrials.gov registry entry for NCT03840837 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivastigmine transdermal patch is the first listed.
NCT03840837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03840837 about?
NCT03840837 is a clinical study titled "Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease". This is a single-site non-randomized open label pilot study. The investigators will use accelerometer-based instrumented gait analysis and computerized cognitive testing to study the interaction of motor and cognitive dysfunction in Parkinson disease dementia (PDD), and the effect of rivastigmine on...
What is the current status of trial NCT03840837?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2019-05-02. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT03840837?
The interventions under investigation include: Rivastigmine transdermal patch (DRUG).
Who is sponsoring clinical trial NCT03840837?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.